ReviewInternational journal of clinical oncology2009
Significance of sentinel lymph node biopsy in malignant melanoma: overview of international data.
Review in International journal of clinical oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Sentinel lymph node biopsy in melanoma: our 8-year clinical experience in a single French institute (2002-2009).BMC dermatology · 2012Article
- The diagnostic value of adding dynamic scintigraphy to standard delayed planar imaging for sentinel node identification in melanoma patients.European journal of nuclear medicine and molecular imaging · 2011Article
- High FOXP3+ regulatory T-cell density in the sentinel lymph node is associated with downstream non-sentinel lymph-node metastasis in gastric cancer.British journal of cancer · 2011Article
- Surgery of primary melanomas.Cancers · 2010Article
- Sentinel lymph node biopsy in melanoma management: its significance and potential problems.International journal of clinical oncology · 2009Article
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The notion of sentinel lymph node (SLN) mapping and its use during surgery for staging cancer was initially reported in 1992, in a study involving patients with malignant melanoma. To date SLN biopsy (SLNB) has emerged as a rational approach for staging regional lymph nodes in patients with clinically node-negative melanoma (stage I and II disease). The significance of SLNB as a staging and prognostic tool in melanoma is widely accepted. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of the SLN remains very controversial. Whether SLNB improves survival in melanoma patients remains an open question.
Indexed as
Identifiers
19967482What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.